Symphogen has opened its US headquarters in Princeton, New Jersey. Adriann Sax, Symphogen’s recently appointed chief business officer, will head the company’s US business which will operate as Symphogen.
Adriann Sax, chief business officer of Symphogen, said: “Antibody therapeutics and technologies continue to drive significant value for the pharmaceutical industry. New Jersey has long been recognised as good centralised location for bioscience companies with global development programs and multiple worldwide partnerships, so it was an easy decision for Symphogen to base our US business here.
“With Symphogen’s pipeline and antibody discovery and expression technologies, we are excited about the company’s future prospects and hope to capitalise on these opportunities by having broad access to physicians, patients and partners.”
Kirsten Drejer, CEO of Symphogen, said: “This is the optimal time to strengthen Symphogen’s global presence as our novel pipeline is advancing into the later-stages of clinical development.”